Search Results for “HIV” – Page 9 – media

75.4 billion! Abbott’s Q3 performance exceeded expectations

Yesterday (October 17th), Abbott announced its third quarter 2024 financial report on its official WeChat account. Abbott’s global sales in the third quarter reached 10.6 billion US dollars (approximately 75.48 billion yuan), with an organic growth of 8.2% and a reported sales growth of 4.9%. Based on the brilliant performance in this quarter, Abbott said that after excluding the impact of COVID-19 testing products, the company expects global sales to achieve an organic growth of 9.5% to 10.0% in 2024, and diluted earnings per share after adjustment for the whole year may be between 4.64 and 4.70 dollars, the median of the range is higher than the previous estimate. Continuous growth achieved through multiple business operations According to the financial report, Abbott’s multiple departments have achieved business growth. Among them, the medical device department achieved double-digit growth, with global sales reaching $4.7 billion in the third quarter, an organic growth ...
- Source: drugdu
- 74
- October 23, 2024
7 Innovative Medical Devices Enter Special Review Process

Recently, the National Medical Products Administration’s Device Review Center released the results of the special review application for innovative medical devices (No. 9 of 2024), intending to approve 7 innovative medical device projects to enter the special review process.1. Liver low-temperature perfusion system: Hangzhou Lepusheng Medical Technology Co., Ltd Hangzhou Lepusheng Medical Technology Co., Ltd. (hereinafter referred to as Lepusheng Medical) was founded in 2016, focusing on the independent research and development of advanced medical devices for the protection, preservation, repair, and transportation of transplanted organs. It is committed to becoming a domestic benchmark and a global leading solution provider in the field of organ perfusion preservation and resuscitation. Since its establishment, Lepusheng Medical has made breakthroughs in core technologies such as organ perfusion protection and transport repair, and is opening up a new model for organ protection in China. The research and development focus of Lepusheng Medical is on ...
- Source: drugdu
- 72
- October 23, 2024
Folagliptin benzoate tablets

According to the authoritative forecast of the International Diabetes Federation, the number of diabetes patients in China may increase to 174 million in 2045! This number really shocked the Chinese people. Are there really so many? You know, the number of diabetes patients in China in 2023 will reach 141 million, with an incidence rate of 12.8%. The number of diabetes patients in China ranks first in the world! In recent years, diabetes has become younger in China. According to a report in 2020, the prevalence of diabetes among residents aged 18 and above in China has reached 11.9%. This set of data once again sounded the alarm for the health of the Chinese people! You should know that diabetes is a chronic disease, and its typical symptoms are “three more and one less”. “Three more” means drinking more, eating more, and urinating more; “one less” mainly refers to weight ...
- Source: drugdu
- 59
- October 22, 2024
2.5 billion! Haoluo Jie has obtained the world’s only uterine ablation product

On October 15th, Hologic Corporation (hereinafter referred to as Hologic) announced that it had reached a final acquisition agreement with Gynesonics for approximately $350 million (approximately RMB 2.5 billion). With this acquisition, Haoluo Jie will further expand its layout in women’s health products to consolidate its leading position in global women’s health. Acquiring innovative products The Gynesonics company acquired this time is an innovative women’s healthcare company headquartered in California, USA. Since its establishment in 2005, we have been committed to providing safe and effective minimally invasive treatment solutions for women with symptomatic uterine fibroids. The Sonata system, the core product of Gynesonics, is the world’s first and only FDA approved diagnostic intrauterine imaging device that can treat specific symptomatic uterine fibroids, including fibroids associated with severe menstrual bleeding, through the cervix. This is also the purpose of Haoluo Jie’s huge investment in acquisition.  The Sonata system consists of ...
- Source: drugdu
- 64
- October 19, 2024
A medical device enters the innovation channel

Recently, the Shanghai Medical Products Administration announced that in accordance with the requirements of the “Special Review Procedure for Class II Innovative Medical Devices in Shanghai”, the Shanghai Medical Products Administration has organized relevant experts to review the special review application for Class II innovative medical devices in the city, and intends to agree to allow Shanghai Futuo Zhida Medical Technology Co., Ltd. (hereinafter referred to as “Futuo Zhida”) to enter the special review procedure for its disposable pulmonary nodule three-dimensional identification positioning marker. Developing innovative technologies with AR navigation systems Founded in 2018, Futo Zhida is a subsidiary of Fosun Pharma, focusing on innovative medical devices and surgical development. Its team has rich experience and a global perspective in the development of image navigation algorithms, intervention consumables design, and production. According to the Chinese Journal of Tuberculosis and Respiratory Sciences, the incidence rate and mortality of lung cancer rank ...
- Source: drugdu
- 62
- October 18, 2024
WuXi AppTec frequently mentioned this word during its Investor Day. Where does the confidence come from?

Recently, WuXi AppTec held an investor open day event called “CRDMO Ultimate Empowerment Journey”. At the event, WuXi AppTec executives mentioned the word “far ahead” many times. Although they said it with a calm face, the message they conveyed was “low-pitched and high-profile”, which won many applause and laughter from the audience. Why can they say that? Where does the confidence come from? If you really achieve “far ahead”, what is the secret? I just came back from WuXi AppTec’s investor day event, and I will highlight the key points for you. Both quantity and quality, the industry contribution is “far ahead” From the perspective of molecular types, the current research and development of small molecules is still the “main force” of current research and development and listing. Whether it is the number of drugs approved by the US FDA or the number of molecular pipelines under development, small molecules ...
- Source: drugdu
- 78
- October 18, 2024
460 million! Migraine innovative equipment company completes Series B financing

Recently, migraine innovative equipment company ShiraTronics announced the completion of a Series B financing of $66 million (approximately RMB 460 million) to support its innovative migraine treatment system. This round of financing is led by new investor Norwest Venture Partners, with other new investors including Seroba, OSF Ventures, Global BioAccess Fund, and an undisclosed strategic investor. In addition, some existing investors such as U S. Venture Partners, Amzak Health, Treo Ventures, and Aperture Venture Partners also participated in this round of financing. The world’s first medical device to treat migraine ShiraTronics, located in Minneapolis, Minnesota, is a clinical stage medical device company dedicated to developing neurostimulation therapies for chronic migraine patients. It is committed to improving the lives of chronic migraine patients and was awarded the FDA Breakthrough Device designation in 2021. The name migraine is not unfamiliar and is often heard in daily life, so the migraine market is ...
- Source: drugdu
- 62
- October 16, 2024
After the 2024 Nobel Prize is announced, what is the commercial value?

The 2024 Nobel Prize in Physiology or Medicine has finally been announced, and surprisingly, the previously highly requested GLP-1 target and alphafold system have not been awarded, and the award-winning fields are similar to last year, which are pioneers in the field of RNA. Last year it was mRNA, this year it is microRNA. On October 7 at 5:30 p.m., the Sweden Carolinska Institutet announced that the 2024 Nobel Prize in Physiology or Medicine was awarded to Victor Ambros and Gary Ruvkun · · for their “discovery of microRNAs and their role in post-transcriptional gene regulation.” It is reported that the two are professors at the University of Massachusetts Medical School and Harvard Medical School, respectively. As we all know, the winner of the Nobel Prize needs to go through a long time from making relevant achievements to winning the Nobel Prize: the Nobel Prize needs time to test its ...
- Source: drugdu
- 86
- October 15, 2024
InnoCare’s “novel TYK2 inhibitor” ushered in progress

Recently, InnoCare announced that the Phase II clinical study of ICP-488, a novel self-developed tyrosine kinase 2 (TYK2) inhibitor, in the treatment of moderate to severe plaque psoriasis, met the primary endpoint. In patients treated for 12 weeks, ICP-488 demonstrated superior efficacy and safety. ICP-488 met multiple efficacy endpoints in the once-in-a-day 6 mg and once-daily 9 mg dose groups, including Psoriasis Area and Severity Index (PASI) 75, PASI 90, PASI 100 (PASI score improvement from baseline ≥75%, ≥90%, and ≥100%), and static Clinician’s Global Assessment (sPGA) 0/1 (i.e., complete or basic clearance of lesions). The response rate of PASI 75 was 77.3% and 78.6%, respectively, in the once-daily 6 mg and 9 mg dose groups, compared with 11.6% in the placebo group (p<0.0001). The response rate of PASI 90 in the two dose groups reached 36.4% and 50.0%, respectively, compared with 0% in the placebo group (p<0.0001); The response ...
- Source: drugdu
- 71
- October 15, 2024
HUTCHMED’s Elunate ® (fruquintinib) was fully funded for inclusion in the Hong Kong Hospital Authority’s Drug Formulary

Chi-Med (China) Limited (“HUTCHMED”) today announced that Elunate ® (fruquintinib) has been added to the Drug Formulary of the Hong Kong Hospital Authority (“HA”) in the category of “Specialty Drugs”. Patients who are prescribed the new drug for specific clinical applications in public hospitals or clinics are only required to pay the standard fee. Elunate ® received approval from the Pharmacy and Poisons Board of Hong Kong in January 2024 for the treatment of adult patients with metastatic colorectal cancer who have been treated. The first innovative anti-oncology drug to be directly included in the HA’s Drug Formulary category, and the first new drug to be approved under the “1” mechanism of the HA’s Drug Formulary, which was quickly included in the Drug Matrix and the “1” mechanism, helping patients accelerate access to important treatment options. Elunate ® is the first oral targeted therapy approved in Hong Kong for the ...
- Source: drugdu
- 70
- October 15, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.